A Randomized Controlled Trial on Effect of Non-Absorbable Antibiotic, Rifaximin in Patients with Irritable Bowel Syndrome
Authors/Creators
- 1. Tutor, Department of Pharmacology, Jawaharlal Nehru Medical College and Hospital (JLNMCH), Bhagalpur, Bihar
- 2. Professor, Department of Pharmacology, Jawaharlal Nehru Medical College and Hospital (JLNMCH), Bhagalpur, Bihar
Description
Background: The most prevalent functional bowel disorder, irritable bowel syndrome (IBS), has no known cure. Research has shown that bacterial overgrowth plays a role in the pathophysiology of this condition. This study aims to assess the impact of an antibiotic that is not absorbed. The main goal of the trial is to determine whether giving patients with IBS who do not have constipation a 400 mg/d oral rifaximin treatment for 14 days is effective. This study’s secondary goal is to determine if a 14-day treatment of 400 mg of rifaximin taken three times a day is as safe for IBS patients without constipation as a placebo. Methods: We enrolled patients in this two-year, randomized, placebo-controlled study based on Rome III criteria. For two weeks, the treatment group was given 400 mg of rifaximin three times a day. Before being included, at the conclusion of the treatment, and one week after the regimen, each patient had a safety and symptom assessment. The Likert scores of the two groups’ symptoms and the primary endpoint the percentage of patients who experienced satisfactory alleviation from IBS symptoms were compared. Results: The percentage of subjects in the rifaximin arm who had sufficient improvement from their IBS symptoms is higher than that of the placebo (68% vs. 39.1%). Following a two-week course of therapy, there was a sustained significant improvement in both groups’ bloating score (P < 0.002), pain score (P < 0.001), and overall score (P < 0.002) after one additional week. There were no noteworthy side effects noted. Conclusion: Taking 400 mg of rifaximin three times a day for two weeks significantly reduced overall IBS symptoms.
Abstract (English)
Background: The most prevalent functional bowel disorder, irritable bowel syndrome (IBS), has no known cure. Research has shown that bacterial overgrowth plays a role in the pathophysiology of this condition. This study aims to assess the impact of an antibiotic that is not absorbed. The main goal of the trial is to determine whether giving patients with IBS who do not have constipation a 400 mg/d oral rifaximin treatment for 14 days is effective. This study’s secondary goal is to determine if a 14-day treatment of 400 mg of rifaximin taken three times a day is as safe for IBS patients without constipation as a placebo. Methods: We enrolled patients in this two-year, randomized, placebo-controlled study based on Rome III criteria. For two weeks, the treatment group was given 400 mg of rifaximin three times a day. Before being included, at the conclusion of the treatment, and one week after the regimen, each patient had a safety and symptom assessment. The Likert scores of the two groups’ symptoms and the primary endpoint the percentage of patients who experienced satisfactory alleviation from IBS symptoms were compared. Results: The percentage of subjects in the rifaximin arm who had sufficient improvement from their IBS symptoms is higher than that of the placebo (68% vs. 39.1%). Following a two-week course of therapy, there was a sustained significant improvement in both groups’ bloating score (P < 0.002), pain score (P < 0.001), and overall score (P < 0.002) after one additional week. There were no noteworthy side effects noted. Conclusion: Taking 400 mg of rifaximin three times a day for two weeks significantly reduced overall IBS symptoms.
Files
IJPCR,Vol16,Issue4,Article154.pdf
Files
(293.5 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:a51832eac2498057adcc2d47913827b6
|
293.5 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-03-26
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue4,Article154.pdf
- Development Status
- Active
References
- 1. Inadomi JM, Fennerty MB, Bjorkman D. Systematic review: The economic impact of irritable bowel syndrome. Aliment PharmacolTher 2003; 18:671-82. 2. Drossman DA, CorGershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev GastroenterolDisord 2003;3 Suppl 2:S25-34. 3. Scott LJ, Perry CM. Tegaserod. Drugs 1999; 58:491. 4. Razziari E, Delvaux M. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. Mc Lean, VA: Degnon Associates; 2006. 5. Gershon MD, Tack J. The serotonin signaling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132:397-414. 6. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebocontrolled study. Am J Gastroenterol 2003; 98:412-9. 7. Pimentel M, Chatterjee S, Chow EJ, Park S, Kong Y. Neomycin improves constipationpredominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: Subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006; 51:1297-301. 8. Huang DB, DuPont HL. Rifaximin-A novel antimicrobial for enteric infections. J Infect 2005; 50:97-106. 9. Gillis JC, Brogden RN. Rifaximin A review ofits antibacterial activity, pharmacokineticproperties and therapeutic potential in conditionsmediated by gastrointestinal bacteria. Drugs 1995; 49:467-84. 10. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101:326-33. 11. Lembo AZ, Ferreira SF, Ringel NL, et al. Rifaximin for the treatment of diarrheaassociated irritable bowel syndrome: Short term treatment leading to long term sustained response. Gastroenterology 2008; 134:255. 12. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364:22-32. 13. Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive Lactulose hydrogen breath test improves symptoms for at least 3 months. Alimentary PharmacolTher 2012; 36:1084-93. 14. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol 2012; 107:28-35.